105 related articles for article (PubMed ID: 12647011)
1. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).
Callies S; de Alwis DP; Wright JG; Sandler A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2003 Feb; 51(2):107-18. PubMed ID: 12647011
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
[TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
Callies S; de Alwis DP; Harris A; Vasey P; Beijnen JH; Schellens JH; Burgess M; Aarons L
Br J Clin Pharmacol; 2003 Jul; 56(1):46-56. PubMed ID: 12848775
[TBL] [Abstract][Full Text] [Related]
5. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A; Gordon M; De Alwis DP; Pouliquen I; Green L; Marder P; Chaudhary A; Fife K; Battiato L; Sweeney C; Jordan C; Burgess M; Slapak CA
Clin Cancer Res; 2004 May; 10(10):3265-72. PubMed ID: 15161679
[TBL] [Abstract][Full Text] [Related]
6. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Gerrard G; Payne E; Baker RJ; Jones DT; Potter M; Prentice HG; Ethell M; McCullough H; Burgess M; Mehta AB; Ganeshaguru K
Haematologica; 2004 Jul; 89(7):782-90. PubMed ID: 15257929
[TBL] [Abstract][Full Text] [Related]
11. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma.
Morschhauser F; Zinzani PL; Burgess M; Sloots L; Bouafia F; Dumontet C
Leuk Lymphoma; 2007 Apr; 48(4):708-15. PubMed ID: 17454628
[TBL] [Abstract][Full Text] [Related]
13. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
14. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
15. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats.
Anderson BD; May MJ; Jordan S; Song L; Roberts MJ; Leggas M
Drug Metab Dispos; 2006 Apr; 34(4):653-9. PubMed ID: 16434546
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
18. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
Marcelletti JF; Multani PS; Lancet JE; Baer MR; Sikic BI
Leuk Res; 2009 Jun; 33(6):769-74. PubMed ID: 18976810
[TBL] [Abstract][Full Text] [Related]
19. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
